|SEQ_NO||1||Date of announcement||2023/01/16||Time of announcement||13:41:26|
|Subject||Announcement of TTY Biopharm's unaudited income information in December 2022|
|Date of events||2023/01/16||To which item it meets||paragraph 53|
|Statement||1.Date of occurrence of the event:2023/01/16
2.Company name:TTY Biopharm Co., Ltd.
3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):Head office
4.Reciprocal shareholding ratios:N/A
5.Cause of occurrence:TTY Biopharm posted a consolidated net sales of $430,735 thousands (expressed in NT dollars; unaudited), a consolidated operating profit of $60,105 thousands, and a consolidated income before tax of $71,623 thousands in December 2022; net income attributed to stockholders of the company was $32,481 thousands; EPS is $0.13.
Year-to-date consolidated net sales was $5,061,663 thousands (in NT dollars; unaudited), a consolidated operating profit was $1,229,142 thousands and consolidated income before tax was $1,407,753 thousands until December 2022; year-to-date net income attributed to stockholders of the company was $1,093,684 thousands; EPS is $4.40.
7.Any other matters that need to be specified (the information disclosure also meets the requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies):
The numbers above are unaudited. In term of the final net sales and profits, quarterly financial reports audited by independent accountants will prevail.